Vergelijking

Afamelanotide vs. Buserelin

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

75921-69-6

57982-77-1

Molecuulmassa

1646.87 g/mol

1239.42 g/mol

Halfwaardetijd

12 h

geen gegevens

Sequentie

Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2

geen gegevens

Werkingsmechanisme

Afamelanotide

Afamelanotide is a synthetic analogue of α-melanocyte-stimulating hormone. It differs from native α-MSH by two substitutions — norleucine at position 4 and D-phenylalanine at position 7 — which make it metabolically more stable and more potent. As an agonist at the melanocortin-1 receptor (MC1R) on melanocytes, it activates adenylate cyclase, raises cAMP and increases tyrosinase activity via the transcription factor MITF. This shifts pigment synthesis toward eumelanin, which absorbs UV and visible light and has antioxidant properties — the presumed mechanism of photoprotection in EPP.

Buserelin

Buserelin is a potent GnRH agonist: after an initial stimulatory surge ('flare'), continuous receptor occupancy causes downregulation and thereby suppression of LH, FSH and the downstream sex hormones.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Afamelanotide	Buserelin
Duitsland	Op recept	Op recept
EU	Op recept	—
Verenigde Staten	Op recept	Niet goedgekeurd

Volledige vermeldingen

Afamelanotide

Volledige vermelding →

Buserelin

Volledige vermelding →

Frequently asked questions

What is the difference between Afamelanotide and Buserelin?: Afamelanotide is classified as "Onderzoek (overig)", while Buserelin is classified as "Onderzoek (overig)". Afamelanotide: Afamelanotide (brand name Scenesse) is a synthetic 13-amino-acid analogue of α-melanocyte-stimulating hormone (α-MSH) and a melanocortin-1 receptor agonist. Unlike most peptides covered here, it is a regularly approved medicine: EMA approval in 2014/2015, FDA approval in 2019, in each case as a subcutaneous implant for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP). It promotes eumelanin formation in the skin. Buserelin: Buserelin is a synthetic GnRH agonist (including as a nasal spray). It is used in endometriosis, hormone-dependent prostate cancer and assisted reproduction; approved in Europe (Suprefact), not in the US. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Afamelanotide or Buserelin?: The highest available evidence level is "Humane RCT" for Afamelanotide and "Humane RCT" for Buserelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Afamelanotide and Buserelin in Germany and the United States?: Duitsland: Afamelanotide — Op recept, Buserelin — Op recept. Verenigde Staten: Afamelanotide — Op recept, Buserelin — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.

Country

Afamelanotide

Buserelin

Duitsland

Op recept

—

Verenigde Staten

Op recept

Niet goedgekeurd

Frequently asked questions

What is the difference between Afamelanotide and Buserelin?

Afamelanotide is classified as "Onderzoek (overig)", while Buserelin is classified as "Onderzoek (overig)". Afamelanotide: Afamelanotide (brand name Scenesse) is a synthetic 13-amino-acid analogue of α-melanocyte-stimulating hormone (α-MSH) and a melanocortin-1 receptor agonist. Unlike most peptides covered here, it is a regularly approved medicine: EMA approval in 2014/2015, FDA approval in 2019, in each case as a subcutaneous implant for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP). It promotes eumelanin formation in the skin. Buserelin: Buserelin is a synthetic GnRH agonist (including as a nasal spray). It is used in endometriosis, hormone-dependent prostate cancer and assisted reproduction; approved in Europe (Suprefact), not in the US. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Afamelanotide or Buserelin?

The highest available evidence level is "Humane RCT" for Afamelanotide and "Humane RCT" for Buserelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Afamelanotide and Buserelin in Germany and the United States?

Duitsland: Afamelanotide — Op recept, Buserelin — Op recept. Verenigde Staten: Afamelanotide — Op recept, Buserelin — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.